National Foundation for Cancer Research
Apr 12, 2025, 06:35
BTOG – Osimertinib Plus Chemotherapy in EGFR-Mutant Advanced NSCLC
BTOG posted on X:
“BTOG wishes to inform members of a new NICE release that has been published today.
NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced non-small-cell lung cancer (NSCLC) in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Please refer to NHS England’s clinical treatment criteria (Blueteq form).
For full details and the documents, please see the NICE website.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 00:00
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32